铁调素在肾性贫血中的研究进展

Advances of hepcidin in renal anemia

贫血是慢性肾脏病患者晚期常见并发症,铁缺乏是肾性贫血发生的重要原因,纠正铁缺乏是肾性贫血治疗中的一个重要环节。铁调素是一种多肽类激素,主要在肝脏内表达,参与调节机体铁代谢。铁调素的表达受机体各种信号因子的影响,通过激活其信号通路,从而可以调控铁调素表达。铁调素可通过结合靶细胞表面膜转铁蛋白,使其降解、失活,抑制细胞铁吸收及铁释放发挥作用。慢性肾脏病患者体内血清铁调素水平与铁代谢、炎症等密切相关。铁负荷、炎症刺激等可使铁调素水平升高,从而促进肾性贫血的发展。通过抑制铁调素生成或阻断其表达过程,铁调素将成为改善肾性贫血的治疗靶点,为肾性贫血提供新的治疗方案。

Anemia is a common complication in patients with chronic kidney disease.Iron deficiency is an important cause of renal anemia,and it is an important part of the treatment of renal anemia.Hepcidin,a peptide hormone,is mainly expressed in the liver and participates in the regulation of iron metabolism.The expression of hepcidin is affected by various signaling factors of the body,and the expression of hepcidin can be regulated by activating its signaling pathway.Hepcidin can bind to transferrin on the surface of target cells to degrade and inactivate it,thereby inhibiting iron absorption and release of cells.The serum hepcidin levels in patients with chronic kidney disease are closely related to iron metabolism and inflammation and other factors.Iron load and inflammatory stimulation can increase hepcidin levels,thereby promoting the development of renal anemia.By inhibiting hepcidin production or blocking its expression process,hepcidin will become a therapeutic target for improving renal anemia,and provide a new treatment for renal anemia.